Cutler Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Cutler Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,000	Closed	-$5K	–	4596
2019 Q4	$5K	Buy	+4,000	New	+$29.4K	﹤0.01%	3070

Other funds holding SNDX

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cutler Group's SNDX Position: Q2 2021 in Review

Cutler Group sold out of Syndax Pharmaceuticals (SNDX) in Q2 2021, closing a stake of 1,500 shares — an estimated $33K sold.

Cutler Group first reported a position in SNDX in Q2 2018 and held it in 6 quarters. The position peaked at $33K in Q1 2021. 115 funds tracked by Wall St. Rank hold SNDX as of Q2 2021.

Cutler Group reported no remaining Syndax Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Cutler Group sold 1,500 Syndax Pharmaceuticals shares in Q2 2021, an estimated $33K.
Cutler Group first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 6 quarters.
Cutler Group's Syndax Pharmaceuticals position peaked at $33K in Q1 2021.
115 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2021.

Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.